ACTRN12610000518066尚未招募未知
aser vapourization of the prostate in men with benign prostate enlargement. Long term results and cost analysis.
Philip McCahy0 个研究点目标入组 150 人开始时间: 2010年6月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 50 Years 至 85 Years（—）
- 性别
- Male
入选标准
- •Urinary flow rate < 15mls/sec, IPSS > 12
排除标准
- •Prostate cancer, inability to provide informed consent
研究者
相似试验
已完成
不适用
aser enucleation of the prostate for benign prostatic hyperplasiaN40Hyperplasia of prostateDRKS00008206Asklepios Klinik Barmbek110
已完成
不适用
sing a high-power thulium laser system in the operation to treat benign prostate hyperplasiarinary frequency, nocturia, weak stream, or urine retentionUrological and Genital DiseasesISRCTN52339705Taipei Veterans General Hospital35
招募中
不适用
Embolisation of the prostatic artery in patients with symptomatic benign prostate hyperplasia: A prospective single arm cohort-study.benign prostate hypertrofiabenign prostate tumour10038593NL-OMON52683Sint Elisabeth Ziekenhuis25
进行中（未招募）
不适用
A Clinical Phase II Study in Patients with Prostate Cancer and Bone Metastases with KML001 (KOMINOX®) - KML001 in patients with prostate cancer and bone metastasesProstate Cancer MetastaticMedDRA version: 8.1Level: LLTClassification code 10036909Term: Prostate cancer metastaticEUCTR2006-005607-33-DEKOMINOX USA, Inc.
尚未招募
不适用
In patients with benign prostate hyperplasia who received tamsulosin 0.2 mg for more than 4 weeks, the improvement of the lower urinary tract symptom terazosin 5 mg administered for 12 weeksKCT0004566Dankook Univeristy Hospital51